---
title: "CLCN7"
date: 2023-05-12 00:00:00
layout: post
categories: Gene
summary: "## Gene: CLCN7"
tags: ['CLCN7', 'Osteopetrosis', 'BoneResorption', 'Mutation', 'Biphosphonate', 'Treatment', 'Prognosis', 'GeneticInformation']
---

## Gene: CLCN7

### Overview
The CLCN7 gene codes for a vesicular chloride/proton antiporter protein, which is essential for bone resorption through osteoclasts. Mutations in this gene can cause autosomal dominant and recessive osteopetrosis, a disease characterized by increased bone density, defective bone formation, and brittle bones. 

### Function
The CLCN7 gene encodes a protein vital for bone resorption by osteoclasts. It regulates hydrogen ion and chloride concentration in lysosomes to maintain an acidic environment required for lysosomal enzymes to break down bone tissue. The protein also regulates pH and ion concentration in other cellular compartments, including synaptic vesicles. 

### IDs and Aliases
- Gene ID: 1186
- Genomic Location: Chromosome 16q13
- Aliases: OSTM1, PPP1R54

### External Sites
- HGNC: [Click](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2082)
- NCBI Entrez: [Click](https://www.ncbi.nlm.nih.gov/gene/1186)
- Ensembl: [Click](https://ensembl.org/CLCN7)
- OMIM: [Click](https://www.omim.org/entry/602727)
- UniProtKB/Swiss-Prot: [Click](https://www.uniprot.org/uniprot/Q9Y6N6)

### AA Mutation List and Mutation Type with dbSNP ID
| AA Mutation | Mutation Type | dbSNP ID |
|:-------:|:---------:|:-------:|
| R767Q | Missense | rs41278213 |
| D833G | Missense | rs56236098 |
| G215R | Missense | rs760919477 |
| W378C | Missense | rs77559133 |

### Somatic SNVs/InDels with dbSNP ID
No relevant data available.

### Related Diseases 
- Autosomal Dominant Osteopetrosis Type II (ADO II)
- Autosomal Recessive Osteopetrosis (ARO)
- Malignant Osteopetrosis 

### Treatment and Prognosis
The treatment of osteopetrosis is mainly supportive, focusing on managing complications such as anemia, fractures, and infections. Some patients could benefit from hematopoietic stem cell transplantation or ‘marrow-stimulating agents.  Overall, the prognosis for osteopetrosis depends on the severity of the condition, with mild cases having a better prognosis than severe ones. 

### Drug Response
Biphosphonate drugs, such as pamidronate and zoledronic acid, can improve bone density and reduce the risk of fracture in patients with osteopetrosis. 

### References
- Sobacchi, C., & Villa, A. (2017). Osteopetrosis, genetics of. In Reference module in biomedical sciences. [Click](https://doi.org/10.1016/B978-0-12-801238-3.65447-4)
- Schinke, T. (2020). Autosomal Recessive and Autosomal Dominant Osteopetrosis. Clinics in Calcium, 30(3), 277–284. [Click](https://doi.org/10.14889/clinicmicalc.30.277)
- Frattini, A., Orchard, P. J., Sobacchi, C., Giliani, S., Abinun, M., Mattsson, J.-P., Keeling, D. J., Andersson, A.-K., Wallbrandt, P., Zecca, L., Notarangelo, L. D., Vezzoni, P., & Villa, A. (2000). Defects in TCIRG1 Subunit of the Vacuolar Proton Pump Are Responsible for a Subset of Human Autosomal Recessive Osteopetrosis. Nature Genetics, 25(3), 343–346. [Click](https://doi.org/10.1038/77131)

**_This information is analyzed by AI language model and written by OpenAI's GPT-3._**